Anteris Technologies Global Corp. ( (AVR) ) has released its Q3 earnings. Here is a breakdown of the information Anteris Technologies Global Corp. presented to its investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Anteris Technologies Global Corp. is a global structural heart company focused on designing, developing, and commercializing innovative medical devices to restore healthy heart function, primarily operating in the medical device sector.
In its latest earnings report for the third quarter of 2025, Anteris Technologies highlighted significant progress in regulatory approvals and operational readiness for its PARADIGM Trial, a pivotal study aimed at evaluating its DurAVR® Transcatheter Heart Valve (THV). The company has received FDA approval to commence patient recruitment in the U.S. and has begun treating patients in Denmark following European regulatory approval.
Key financial metrics for the quarter include net operating cash outflows of $59.3 million, primarily driven by increased clinical, regulatory, and manufacturing activities to support the PARADIGM Trial. Research and development expenses amounted to $16.8 million, reflecting the company’s focus on trial preparations and manufacturing scale-up. Selling, general, and administrative expenses were reported at $5.8 million, with cash and cash equivalents totaling $9.1 million as of September 30, 2025.
Anteris is advancing its quality management system and manufacturing capabilities to support the anticipated demand for its DurAVR® THV. The company is committed to providing robust clinical evidence through the PARADIGM Trial, which aims to secure FDA Premarket Approval and CE Mark approval in parallel.
Looking ahead, Anteris Technologies remains focused on executing its strategic initiatives and advancing its clinical trials, positioning itself for potential growth in the structural heart disease market.